Case Report: Transplantation of Human Induced Pluripotent Stem Cell-derived Cardiomyocyte Patches for Ischemic Cardiomyopathy

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2022 Sep 2

PMID 36051285

Authors

Shigeru Miyagawa

Satoshi Kainuma

Takuji Kawamura

Kota Suzuki

Yoshito Ito

Hiroko Iseoka

Emiko Ito

Maki Takeda

Masao Sasai

Noriko Mochizuki-Oda

Tomomi Shimamoto

Yukako Nitta

Hiromi Dohi

Tadashi Watabe

Yasushi Sakata

Koichi Toda

Yoshiki Sawa

Affiliations

Soon will be listed here.

Abstract

Despite major therapeutic advances, heart failure, as a non-communicable disease, remains a life-threatening disorder, with 26 million patients worldwide, causing more deaths than cancer. Therefore, novel strategies for the treatment of heart failure continue to be an important clinical need. Based on preclinical studies, allogenic human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) patches have been proposed as a potential therapeutic candidate for heart failure. We report the implantation of allogeneic hiPSC-CM patches in a patient with ischemic cardiomyopathy (ClinicalTrials.gov, #jRCT2053190081). The patches were produced under clinical-grade conditions and displayed cardiogenic phenotypes and safety (severe immunodeficient mice) without any genetic mutations in cancer-related genes. The patches were then implanted via thoracotomy into the left ventricle epicardium of the patient under immunosuppressive agents. Positron emission tomography and computed tomography confirmed the potential efficacy and did not detect tumorigenesis in either the heart or other organs. The clinical symptoms improved 6 months after surgery, without any major adverse events, suggesting that the patches were well-tolerated. Furthermore, changes in the wall motion in the transplanted site were recovered, suggesting a favorable prognosis and the potential tolerance to exercise. This study is the first report of a successful transplant of hiPSC-CMs for severe ischemic cardiomyopathy.

Citing Articles

A Platform Integrating Biophysical and Biochemical Stimuli to Enhance Differentiation and Maturation of Cardiomyocyte Subtypes Derived from Human Induced Pluripotent Stem Cells.

Feng Z, Sawada K, Ando I, Yoshinari R, Sato D, Kosawada T J Cardiovasc Dev Dis. 2025; 12(2).

PMID: 39997490 PMC: 11856794. DOI: 10.3390/jcdd12020056.

Systemic administration of induced pluripotent stem cell-derived mesenchymal stem cells improves cardiac function through extracellular vesicle-mediated tissue repair in a rat model of ischemic cardiomyopathy.

Kawasumi R, Kawamura T, Yamashita K, Tominaga Y, Harada A, Ito E Regen Ther. 2025; 28():253-261.

PMID: 39834593 PMC: 11745812. DOI: 10.1016/j.reth.2024.12.008.

Proteomic Approach Using DIA-MS Identifies Morphogenesis-Associated Proteins during Cardiac Differentiation of Human iPS Cells.

Urasawa T, Kawasaki N ACS Omega. 2025; 10(1):344-357.

PMID: 39829588 PMC: 11740111. DOI: 10.1021/acsomega.4c06371.

Revolutionizing cardiovascular research: Human organoids as a Beacon of hope for understanding and treating cardiovascular diseases.

Li J, Li Y, Song G, Wang H, Zhang Q, Wang M Mater Today Bio. 2025; 30():101396.

PMID: 39802826 PMC: 11719415. DOI: 10.1016/j.mtbio.2024.101396.

Current Advances and Future Directions of Pluripotent Stem Cells-Derived Engineered Heart Tissue for Treatment of Cardiovascular Diseases.

He X, Good A, Kalou W, Ahmad W, Dutta S, Chen S Cells. 2025; 13(24).

PMID: 39768189 PMC: 11674482. DOI: 10.3390/cells13242098.

References

Patila T, Miyagawa S, Imanishi Y, Fukushima S, Siltanen A, Mervaala E . Comparison of arrhythmogenicity and proinflammatory activity induced by intramyocardial or epicardial myoblast sheet delivery in a rat model of ischemic heart failure. PLoS One. 2015; 10(4):e0123963. PMC: 4393220. DOI: 10.1371/journal.pone.0123963. View

Fallavollita J, Perry B, Canty Jr J . 18F-2-deoxyglucose deposition and regional flow in pigs with chronically dysfunctional myocardium. Evidence for transmural variations in chronic hibernating myocardium. Circulation. 1997; 95(7):1900-9. DOI: 10.1161/01.cir.95.7.1900. View

Higuchi T, Miyagawa S, Pearson J, Fukushima S, Saito A, Tsuchimochi H . Functional and Electrical Integration of Induced Pluripotent Stem Cell-Derived Cardiomyocytes in a Myocardial Infarction Rat Heart. Cell Transplant. 2015; 24(12):2479-89. DOI: 10.3727/096368914X685799. View

Shiba Y, Gomibuchi T, Seto T, Wada Y, Ichimura H, Tanaka Y . Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts. Nature. 2016; 538(7625):388-391. DOI: 10.1038/nature19815. View

Ito E, Miyagawa S, Yoshida Y, Sawa Y . Efficient Method to Dissociate Induced Pluripotent Stem Cell-Derived Cardiomyocyte Aggregates into Single Cells. Methods Mol Biol. 2021; 2320:29-33. DOI: 10.1007/978-1-0716-1484-6_4. View

Miyagawa S, Kawamura T, Ito E, Takeda M, Iseoka H, Yokoyama J . Pre-clinical evaluation of the efficacy and safety of human induced pluripotent stem cell-derived cardiomyocyte patch. Stem Cell Res Ther. 2024; 15(1):73. PMC: 10935836. DOI: 10.1186/s13287-024-03690-8. View

Cohn J . Heart failure in 2013: Continue what we are doing to treat HF, but do it better. Nat Rev Cardiol. 2013; 11(2):69-70. DOI: 10.1038/nrcardio.2013.212. View

Kawamura M, Miyagawa S, Fukushima S, Saito A, Miki K, Ito E . Enhanced survival of transplanted human induced pluripotent stem cell-derived cardiomyocytes by the combination of cell sheets with the pedicled omental flap technique in a porcine heart. Circulation. 2013; 128(11 Suppl 1):S87-94. DOI: 10.1161/CIRCULATIONAHA.112.000366. View

Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K . Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131(5):861-72. DOI: 10.1016/j.cell.2007.11.019. View

10.

Iseoka H, Miyagawa S, Fukushima S, Saito A, Masuda S, Yajima S . Pivotal Role of Non-cardiomyocytes in Electromechanical and Therapeutic Potential of Induced Pluripotent Stem Cell-Derived Engineered Cardiac Tissue. Tissue Eng Part A. 2017; 24(3-4):287-300. PMC: 5792250. DOI: 10.1089/ten.TEA.2016.0535. View

11.

Ito E, Miyagawa S, Takeda M, Kawamura A, Harada A, Iseoka H . Tumorigenicity assay essential for facilitating safety studies of hiPSC-derived cardiomyocytes for clinical application. Sci Rep. 2019; 9(1):1881. PMC: 6374479. DOI: 10.1038/s41598-018-38325-5. View

12.

Longnus S, Mathys V, Dornbierer M, Dick F, Carrel T, Tevaearai H . Heart transplantation with donation after circulatory determination of death. Nat Rev Cardiol. 2014; 11(6):354-63. DOI: 10.1038/nrcardio.2014.45. View

13.

Nakagawa M, Taniguchi Y, Senda S, Takizawa N, Ichisaka T, Asano K . A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells. Sci Rep. 2014; 4:3594. PMC: 3884228. DOI: 10.1038/srep03594. View

14.

Takahashi K, Yamanaka S . Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126(4):663-76. DOI: 10.1016/j.cell.2006.07.024. View

15.

Abraham W, Smith S . Devices in the management of advanced, chronic heart failure. Nat Rev Cardiol. 2012; 10(2):98-110. PMC: 3753073. DOI: 10.1038/nrcardio.2012.178. View

16.

Yoshida S, Miyagawa S, Toyofuku T, Fukushima S, Kawamura T, Kawamura A . Syngeneic Mesenchymal Stem Cells Reduce Immune Rejection After Induced Pluripotent Stem Cell-Derived Allogeneic Cardiomyocyte Transplantation. Sci Rep. 2020; 10(1):4593. PMC: 7067786. DOI: 10.1038/s41598-020-58126-z. View

17.

Bolli R, Marban E . Molecular and cellular mechanisms of myocardial stunning. Physiol Rev. 1999; 79(2):609-34. DOI: 10.1152/physrev.1999.79.2.609. View

18.

Kawamura M, Miyagawa S, Miki K, Saito A, Fukushima S, Higuchi T . Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. Circulation. 2012; 126(11 Suppl 1):S29-37. DOI: 10.1161/CIRCULATIONAHA.111.084343. View